Jennifer J. Rhodes - 06 Feb 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, CHIEF LEGAL OFFICER, SEC
Signature
/s/ Jennifer J. Rhodes
Issuer symbol
ACAD
Transactions as of
06 Feb 2026
Net transactions value
-$162,491
Form type
4
Filing time
10 Feb 2026, 18:00:04 UTC
Previous filing
26 Mar 2025
Next filing
10 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Rhodes Jennifer J EVP, CHIEF LEGAL OFFICER, SEC C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO /s/ Jennifer J. Rhodes 10 Feb 2026 0001568249

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $0 +12,944 +801% $0.000000 14,559 06 Feb 2026 Direct F1, F2
transaction ACAD Common Stock Sale $162,491 -6,950 -48% $23.38 7,609 09 Feb 2026 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -12,944 -50% $0.000000 12,945 06 Feb 2026 Common Stock 12,944 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 595 shares of the Issuer's common stock acquired by the reporting person on May 15, 2025 pursuant to an employee stock purchase plan.
F3 The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.38 to $23.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 50% of the restricted stock units vested on February 6, 2026 and 25% vest on each of February 6, 2027 and February 6, 2028.